Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2008

LabCorp to Commercialize Lung Cancer Detection Device with Right’s from Duke University

  • Laboratory Corporation of America (LabCorp) entered into an exclusive license agreement with Duke University Medical Center to commercialize the institute’s blood-based assay for early detection of lung cancer.

    The Duke technology is based on a collection of serum proteins associated with the biology of lung cancer. Duke and LabCorp expect to conduct additional clinical studies with the biomarker technology prior to its commercial introduction.

    “Our goal is to develop a cutting-edge technology that when combined with other modalities such as CT imaging can better differentiate true cancers from benign nodules,” says Edward Patz, M.D., James and Alice Chen professor of radiology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »